These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38345724)

  • 1. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
    Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
    Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
    Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
    Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
    Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T
    Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours.
    Malarz MM; Birkenfeld B; Piwowarska-Bilska H
    Nucl Med Rev Cent East Eur; 2024; 27(0):31-35. PubMed ID: 39162352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
    Stokkel MP; Rietbergen DD; Korse CM; Taal BG
    Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
    J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
    Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
    Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
    Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
    Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
    Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
    J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
    Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
    Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
    Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
    Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
    Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
    Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.